• Mashup Score: 0

    In this podcast, Prof. Igor Tsaur (DE), chief editor of the UROONCO PCa editorial board talks with Mr. Craig Jones (GB), from Salford Royal and Christie Hospitals, about his recent presentation at AUA2023, “Clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mHSPC).”

    Tweet Tweets with this article
    • 🆕#EAUpodcast 👉 What is the risk of osteoporosis when utilising ADT+Docetaxel compared to ADT+NHA? 🎧Listen to Prof. Tsaur (DE) & Mr. Jones (GB) discussing clinical fracture incidence in #mHSPC & options for risk-reduction #STAMPEDE #ProstateCancer 👉https://t.co/WppYYNzo72 https://t.co/xPeXN1nqP1

  • Mashup Score: 0

    Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE…

    Tweet Tweets with this article
    • Insights from the #STAMPEDE trial platform. @marina_parry & Gerhardt Attard, MD, PhD, FRCP @ucl join @CaPsurvivorship @DanaFarber to discuss two key studies from the STAMPEDE trial platform. #WatchNow on UroToday > https://t.co/P9edl73LhE @AttardLab @Decipher_VCYT https://t.co/3nzHSjVnU4